No significant changes to residual viremia after switch to dolutegravir and lamivudine in a randomized trial

Jonathan Z. Li; Paul E. Sax; Vincent C. Marconi; Jesse Fajnzylber; Baiba Berzins; Amesika N. Nyaku; Carl J. Fichtenbaum; Timothy Wilkin; Constance A. Benson; Susan L. Koletar; Ramon Lorenzo-Redondo; Babafemi O Taiwo

doi:10.1093/ofid/ofz056

No significant changes to residual viremia after switch to dolutegravir and lamivudine in a randomized trial

Jonathan Z. Li^*, Paul E. Sax, Vincent C. Marconi, Jesse Fajnzylber, Baiba Berzins, Amesika N. Nyaku, Carl J. Fichtenbaum, Timothy Wilkin, Constance A. Benson, Susan L. Koletar, Ramon Lorenzo-Redondo, Babafemi O Taiwo

^*Corresponding author for this work

Medicine, Infectious Diseases Division

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

In the ASPIRE trial, antiretroviral therapy (ART) switch to dolutegravir plus lamivudine (DTG+3TC) was comparable to 3-drug ART in maintaining viral suppression by standard viral load assays. We used an ultrasensitive assay to assess whether this switch led to increased residual viremia. At entry, levels of residual viremia did not differ significantly between arms (DTG+3TC vs 3-drug ART: mean, 5.0 vs 4.2 HIV-1 RNA copies/mL; P = .64). After randomization, no significant between-group differences were found at either week 24 or 48. These results show no evidence for increased viral replication on DTG+3TC and support its further investigation as a dual ART strategy.

Original language	English (US)
Article number	56
Journal	Open Forum Infectious Diseases
Volume	6
Issue number	3
DOIs	https://doi.org/10.1093/ofid/ofz056
State	Published - Mar 2019

Funding

This work was supported by an investigator-sponsored study grant from ViiV HealthCare to Northwestern University (NU). V.C.M., C.J.F., C.A.B., T.W., S.L.K., J.C., J.Z.L., and P.E.S. have received grant funding for this study to their institutions through NU from ViiV/GSK. V.C.M. has received funding from the Emory CFAR (P30AI050409).

Keywords

ART simplification
ART switch
Dolutegravir
Lamivudine
Residual viremia

ASJC Scopus subject areas

Infectious Diseases
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/ofid/ofz056

Cite this

Li, J. Z., Sax, P. E., Marconi, V. C., Fajnzylber, J., Berzins, B., Nyaku, A. N., Fichtenbaum, C. J., Wilkin, T., Benson, C. A., Koletar, S. L., Lorenzo-Redondo, R., & Taiwo, B. O. (2019). No significant changes to residual viremia after switch to dolutegravir and lamivudine in a randomized trial. Open Forum Infectious Diseases, 6(3), Article 56. https://doi.org/10.1093/ofid/ofz056

@article{ee6c47aa6d1b4445b4b8a913f9d2e1f7,

title = "No significant changes to residual viremia after switch to dolutegravir and lamivudine in a randomized trial",

abstract = "In the ASPIRE trial, antiretroviral therapy (ART) switch to dolutegravir plus lamivudine (DTG+3TC) was comparable to 3-drug ART in maintaining viral suppression by standard viral load assays. We used an ultrasensitive assay to assess whether this switch led to increased residual viremia. At entry, levels of residual viremia did not differ significantly between arms (DTG+3TC vs 3-drug ART: mean, 5.0 vs 4.2 HIV-1 RNA copies/mL; P = .64). After randomization, no significant between-group differences were found at either week 24 or 48. These results show no evidence for increased viral replication on DTG+3TC and support its further investigation as a dual ART strategy.",

keywords = "ART simplification, ART switch, Dolutegravir, Lamivudine, Residual viremia",

author = "Li, {Jonathan Z.} and Sax, {Paul E.} and Marconi, {Vincent C.} and Jesse Fajnzylber and Baiba Berzins and Nyaku, {Amesika N.} and Fichtenbaum, {Carl J.} and Timothy Wilkin and Benson, {Constance A.} and Koletar, {Susan L.} and Ramon Lorenzo-Redondo and Taiwo, {Babafemi O}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America.",

year = "2019",

month = mar,

doi = "10.1093/ofid/ofz056",

language = "English (US)",

volume = "6",

journal = "Open Forum Infectious Diseases",

issn = "2328-8957",

publisher = "Oxford University Press",

number = "3",

}

TY - JOUR

T1 - No significant changes to residual viremia after switch to dolutegravir and lamivudine in a randomized trial

AU - Li, Jonathan Z.

AU - Sax, Paul E.

AU - Marconi, Vincent C.

AU - Fajnzylber, Jesse

AU - Berzins, Baiba

AU - Nyaku, Amesika N.

AU - Fichtenbaum, Carl J.

AU - Wilkin, Timothy

AU - Benson, Constance A.

AU - Koletar, Susan L.

AU - Lorenzo-Redondo, Ramon

AU - Taiwo, Babafemi O

PY - 2019/3

Y1 - 2019/3

N2 - In the ASPIRE trial, antiretroviral therapy (ART) switch to dolutegravir plus lamivudine (DTG+3TC) was comparable to 3-drug ART in maintaining viral suppression by standard viral load assays. We used an ultrasensitive assay to assess whether this switch led to increased residual viremia. At entry, levels of residual viremia did not differ significantly between arms (DTG+3TC vs 3-drug ART: mean, 5.0 vs 4.2 HIV-1 RNA copies/mL; P = .64). After randomization, no significant between-group differences were found at either week 24 or 48. These results show no evidence for increased viral replication on DTG+3TC and support its further investigation as a dual ART strategy.

AB - In the ASPIRE trial, antiretroviral therapy (ART) switch to dolutegravir plus lamivudine (DTG+3TC) was comparable to 3-drug ART in maintaining viral suppression by standard viral load assays. We used an ultrasensitive assay to assess whether this switch led to increased residual viremia. At entry, levels of residual viremia did not differ significantly between arms (DTG+3TC vs 3-drug ART: mean, 5.0 vs 4.2 HIV-1 RNA copies/mL; P = .64). After randomization, no significant between-group differences were found at either week 24 or 48. These results show no evidence for increased viral replication on DTG+3TC and support its further investigation as a dual ART strategy.

KW - ART simplification

KW - ART switch

KW - Dolutegravir

KW - Lamivudine

KW - Residual viremia

UR - http://www.scopus.com/inward/record.url?scp=85066413129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066413129&partnerID=8YFLogxK

U2 - 10.1093/ofid/ofz056

DO - 10.1093/ofid/ofz056

M3 - Article

C2 - 30895201

AN - SCOPUS:85066413129

SN - 2328-8957

VL - 6

JO - Open Forum Infectious Diseases

JF - Open Forum Infectious Diseases

IS - 3

M1 - 56

ER -

No significant changes to residual viremia after switch to dolutegravir and lamivudine in a randomized trial

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this